ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

9478	Companies
185480	Keywords
117823	Articles
99321	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 07/30/2025 at 07:45, 4 months 6 days ago

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia

Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF

published on 07/24/2025 at 08:01, 4 months 12 days ago

AB Science obtient l'approbation pour une étude de phase 3 sur le masitinib dans la SLA en Europe

Essai De Phase 3 AB Science Masitinib SLA Approbation Européenne
BRIEF

published on 07/24/2025 at 08:01, 4 months 12 days ago

AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe

Phase 3 Trial ALS AB Science Masitinib European Approval
PRESS RELEASE

published on 07/24/2025 at 07:56, 4 months 12 days ago

AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l'étude confirmatoire de phase 3 avec le masitinib dans la sclérose latérale amyotrophique. Protocole validé par l'EMA et autorisation de la FDA

AB Science Masitinib Sclérose Latérale Amyotrophique Étude Confirmatoire Autorisation Européenne
PRESS RELEASE

published on 07/24/2025 at 07:56, 4 months 12 days ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
BRIEF

published on 07/08/2025 at 08:06, 4 months 28 days ago

AB Science Completes EUR 1.925 Million Private Placement

Private Placement Share Issuance Biotech Funding AB Science AB8939 Program
BRIEF

published on 07/08/2025 at 08:06, 4 months 28 days ago

AB Science finalise un placement privé de 1,925 million d'euros

Placement Privé Émission D'actions AB Science Financement Des Biotechnologies Programme AB8939
PRESS RELEASE

published on 07/08/2025 at 08:01, 4 months 28 days ago

AB Science annonce le succès d'un placement privé de 1,925 millions d'euros
AB Science annonce le succès d'un placement privé d'environ 1,925 million d'euros pour financer le développement clinique du programme AB8939

Financement Placement Privé Développement Clinique AB Science Programme AB8939
PRESS RELEASE

published on 07/08/2025 at 08:01, 4 months 28 days ago

AB Science announces the successful completion of a EUR 1.925 million private placement
AB Science successfully completes EUR 1.925 million private placement to finance ongoing activities and focus on AB8939 program development. New shares to be admitted to trading on Euronext Paris

Private Placement Euronext Paris AB Science AB8939 Program EUR 1.925 Million
BRIEF

published on 07/04/2025 at 08:06, 5 months 1 day ago

AB Science : Feu vert pour l'étude de phase 3 du masitinib dans le cancer de la prostate

Phase 3 AB Science Masitinib Cancer De La Prostate FDA Et EMA

Accesswire

Published on 12/05/2025 at 15:00, 24 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 24 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 24 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 12 hours 49 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 12 hours 54 minutes ago

Klondike Gold Announces AGM Results

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 15:05, 19 minutes ago

Seegene Establishes French Subsidiary to Expand European Footprint
Published on 12/05/2025 at 14:22, 1 hour 2 minutes ago

EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 1 hour 8 minutes ago

Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 1 hour 14 minutes ago

The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 1 hour 39 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings

Les Echos

Published on 12/05/2025 at 15:10, 14 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 14 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 26 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 39 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 39 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE